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      Currently, the USA (United States of America) biologicals drugs are the fastest-growing 
sector in the pharmaceutical industry where their market is segmented into two unbalance parts, 
with the smaller portion being under biosimilars competition 
 
        Defined by regulatory agencies in the USA, Europe, and other countries, a biosimilar is a 
highly similar product for a reference licensed biological product, having minor modifications in 
clinically inactive elements, where it was established that both products have no meaningful 
clinical differences in terms of safety, purity, pharmacokinetic “PK”, pharmacodynamic “PD”, 
immunogenicity, and efficacy. 
 
      Today, America’s patients, taxpayers, and healthcare systems are bearing the costs of billions 
of dollars based on the expensive prices of the biological drug.  
Thus, Biosimilars have so much to offer for America’s patients by saving the economy from the 
high burden cost of drug development, but their helping potential is squeezed by roadblocks 
inhibiting their skyrocketing market.  
 
      Mainly these roadblocks are regulatory, non-regulatory barriers, and lack of educational 
knowledge, all of them inhibiting biosimilars from entering strongly and changing the short and 
long outlook of the USA healthcare system.  
     In conclusion, biosimilars will have vast opportunities for America’s future saving, if only 
more tolerant regulations and legislations will be implemented from the part of the congress and 
the FDA by limiting the innovator’s strategic tactics.    
 
